The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center
Abdominal Radiology · 2026
DOI: 10.1007/s00261-026-05519-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Chunxu Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasonography, Sanming First Hospital Affiliated to Fujian Medical University, Sanming, China. Hauptthemen laut MEDLINE: Ultrasonography, Interventional, Liver Neoplasms, Radiofrequency Ablation, Catheter Ablation. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To investigate the effectiveness and safety of ultrasound (US)-guided percutaneous radiofrequency ablation (PRFA) for sub-cardiac hepatic tumors and evaluate the factors influencing local tumor progression (LTP). METHODS: Between January 2016 and January 2023, we included 118 patients (118 lesions) of US-guided RFA for sub-cardiac hepatic tumors (located in S2 or S4a, with a gap between the tumor and the left diaphragm ≤ 10 mm). We retrospectively analyzed patients' electronic medical records and imaging follow-up data to evaluate the success rate, LTP, and complications. We also used univariate and multivariate Cox regression to explore the risk factors for LTP. RESULTS: The primary technical success rate for treating sub-cardiac hepatic tumors was 113/118 (95.8%). The success rate after the second ablation was 118/118 (100%). A single serious complication was recorded 1/118(0.8%), including acute pericardial tamponade and sudden cardiac arrest. The median follow-up period was 24 months (range, 1.2-72 months), with LTP occurring in 19 lesions (16.1%). Besides, the 1-year, 2-year, and 3-year cumulative rates of LTP were 12.7%, 15.3%, and 16.1%, respectively. Tumor size was an independent risk factor for LTP following ablation of sub-cardiac hepatic tumors (HR 1.06; 95% CI 1.02-1.11; P = 0.008). A larger minimal ablative margin (MAM) was associated with a lower hazard of LTP (HR 0.78; 95% CI 0.65-0.92; Wald P = 0.004; LR P = 0.002). Stratified analysis indicated that lesions ≥ 30 mm in diameter carried a significantly higher risk of LTP (HR 4.35; 95% CI 1.46-12.99; P = 0.009). CONCLUSIONS: US-guided PRFA for sub-cardiac hepatic tumors is effective and safe, though caution is advised for tumors ≥ 30 mm due to a significantly higher LTP risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasonography, Sanming First Hospital Affiliated to Fujian Medical University, Sanming, China.
- Department of Ultrasonography, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Department of Ultrasonography, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. 465269898@qq.com.
Zitieren
APA
Liao, C., Yang, J., Hong, Z., Zeng, X., Hu, T., & Wu, S. (2026). The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05519-9
Vancouver
Liao C, Yang J, Hong Z, Zeng X, Hu T, Wu S. The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05519-9
BibTeX
@article{Liao2026,
author = {Liao, Chunxu and Yang, Jianchuan and Hong, ZhiLiang and Zeng, Xiantao and Hu, Ting and Wu, Songsong},
title = {The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05519-9}
}
EUVIMED